soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first Oral Semaglutide Reduces Cardiovascular Events

Extra Strength 300mg Per Serving Each capsule contains 300mg of pure S-Acetyl L-Glutathione, 3x higher then most other formulations

Accessed March 20, 2026 at Aronne LJ, Horn DB, le Roux CW, et al

Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]

This stack is particularly well-suited to people running recomp or performance protocols who want cellular energy production and tissue repair operating at full capacity simultaneously

In this context, white-label means that OpenLoop provides the underlying infrastructure, such as medical staffing, technology platforms and regulatory compliance

How We Got Here: Budget Realignment and Cost Pressures The decision to end GLP-1 coverage didnt come in isolation